反応式
[Br:1][C:2]1[S:6][C:5]([CH:7]2[CH2:12][CH2:11][NH:10][CH2:9][CH2:8]2)=[N:4][C:3]=1[CH2:13][CH2:14][C:15]1[CH:20]=[CH:19][CH:18]=[CH:17][CH:16]=1.[CH3:21][C:22]1[N:26]([CH2:27][C:28](O)=[O:29])[N:25]=[C:24]([C:31]([F:34])([F:33])[F:32])[CH:23]=1>>[Br:1][C:2]1[S:6][C:5]([CH:7]2[CH2:12][CH2:11][N:10]([C:28](=[O:29])[CH2:27][N:26]3[C:22]([CH3:21])=[CH:23][C:24]([C:31]([F:34])([F:33])[F:32])=[N:25]3)[CH2:9][CH2:8]2)=[N:4][C:3]=1[CH2:13][CH2:14][C:15]1[CH:16]=[CH:17][CH:18]=[CH:19][CH:20]=1参加物
3
実験手順
4-[5-Bromo-4-(2-phenylethyl)-1,3-thiazol-2-yl]piperidine (II-3, 127 mg) is reacted analogously to Example I-81 with [5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetic acid (118 mg). After chromatographic purification, this gives 1-{4-[5-bromo-4-(2-phenylethyl)-1,3-thiazol-2-yl]piperidin-1-yl}-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone (52 mg).
後処理
- customAfter chromatographic purification
出典と根拠
- ORDレコード
- ord-d75b1d47eb9449578b9109e441a24501
- 出典データセット
- uspto-grants-2011_05
- 特許番号
- US07943774B2
関連ノート
読み込み中…